Ramucirumab Plus Erlotinib for Previously Untreated EGFR-Mutated Metastatic NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results
ESMO Open 2023 Jun 28;8(4)101580, EB Garon, M Reck, K Nishio, JV Heymach, M Nishio, S Novello, L Paz-Ares, S Popat, SP Aix, H Graham, BD Butts, C Visseren-Grul, K NakagawaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.